Purpose of the development: For the treatment of hypertensive patients with insulin resistance syndrome.

Recommended application field: Medicine. Therapy-cardiology.

Advantages over analogues: Novelty: A collection of application analaprila and moxonidine for correction of endothelial dysfunction. The method introduced in the cardiology, therapeutic departments of Ivano-Frankivsk central city hospital.

The development stage readiness: Introduced in production

Description of the development:
()
A method of treating hypertensive patients with insulin resistance syndrome includes the totality of antihypertensive drugs , which is characterized in that the correction endotelialnoy dysfunction inhibitors are used ангиотензинпреобразовательного fermentaenaloprila maleate 20-40 mg ( 1 tablet 10-20 mg ) per day and imidazoline receptor agonist - moxonidine on 0 2 mg ( 1 tablet 0.2 mg ) once a day treatment for 2 months. Novelty : A collection of application analaprila and moxonidine for correction of endothelial dysfunction. The method introduced in the cardiology , therapeutic departments of Ivano-Frankivsk central city hospital .

Information about newness of the development:
there are Ukrainian patents -- 1 items

Possibility of transfer abroad:
Licence's sale
Licence's sale
Technological document's sale

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua